Bioequivalence study of Gabapentin 300mg capsule of Alborzdarou Pharm Co.,
Not Applicable
- Conditions
- euralgia and neuropathic disorders.
- Registration Number
- IRCT20190706044111N6
- Lead Sponsor
- Alborzdarou Pharm. Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Aged between 20 - 50 years
Body weight between 50 – 100 kg
Having good health on the basis of medical history and physical & clinical examination
Understand the procedures and give written informed consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of gabapentin. Timepoint: 0 (before dosing), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0 & 24.0 hr. after dosing. Method of measurement: HPLC.
- Secondary Outcome Measures
Name Time Method